SCHEMBL14018271

SCHEMBL14018271

FC(F)(F)c1ccc(Oc2cccc(S)c2)c(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
MAPT P10636 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 1/20 0.47
TTR P02766 1/20 0.47
PPOX P50336 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MRGPRX4 Q96LA9 6/20 0.45
STK39 Q9UEW8 1/20 0.45
HTR2A P28223 2/20 0.43
SLC6A4 P31645 2/20 0.43
KCNH2 Q12809 2/20 0.43
EGFR P00533 2/20 0.43
ERBB2 P04626 2/20 0.43
ERBB3 P21860 2/20 0.43
ERBB4 Q15303 2/20 0.43
RAB9A P51151 1/20 0.42
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10538095 0.89 NPSR1 (0.57) FFAR1NPSR1MAPTL3MBTL1MEN1
SCHEMBL11648951 0.85 FFAR1 (0.50) FFAR1NPSR1MAPTL3MBTL1MEN1
SCHEMBL9132379 0.84 FFAR1 (0.49) FFAR1NPSR1MAPTL3MBTL1MEN1
SCHEMBL9003844 0.83 FFAR1 (0.60) FFAR1NPSR1MAPTL3MBTL1MEN1
SCHEMBL7597428 0.82 L3MBTL1 (0.51) FFAR1NPSR1MAPTL3MBTL1MEN1
SCHEMBL8749364 0.82 RAB9A (0.61) FFAR1NPSR1MAPTL3MBTL1MEN1
SCHEMBL8813323 0.82 MRGPRX4 (0.61) FFAR1NPSR1MAPTL3MBTL1MEN1
SCHEMBL11121304 0.82 STK39 (0.50) FFAR1NPSR1MAPTL3MBTL1MEN1
SCHEMBL11046440 0.82 L3MBTL1 (0.70) FFAR1NPSR1MAPTL3MBTL1MEN1
SCHEMBL11214221 0.82 FFAR1 (0.48) FFAR1NPSR1MAPTL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442808-B2 e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia MERCK & CO., INC. (US) 2008-10-28 US disclosed
US-7442808-B2 e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia MERCK & CO., INC. (US) 2008-10-28 US disclosed
WO-2007136572-A2 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK & CO., INC. (US) 2007-11-29 WO disclosed
WO-2007136573-A2 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK & CO., INC. (US) 2007-11-29 WO disclosed
US-20070265332-A1 Antidiabetic bicyclic compounds MERCK SHARP & DOHME LLC 2007-11-15 US disclosed
US-20070265332-A1 Antidiabetic bicyclic compounds MERCK SHARP & DOHME LLC 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265332-A1 Antidiabetic bicyclic compounds GPR119, GPR65, FFAR4 FFAR1 9/4885NPSR1 1233/4885MAPT 3890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.